Patients with atrial fibrillation or an artificial heart valve often
need long-term anticoagulation to reduce their high risk for thrombotic
events. Warfarin and other vitamin K antagonist (VKA) anticoagulants can
prevent thrombosis, but there is an increased risk of major bleeding.
Human prothrombin complex concentrate can be used
more quickly than plasma for reversal of VKA anticoagulation, as it can
be used without blood group typing or thawing. This therapy offers
clinicians a new option for patients requiring urgent reversal of VKA
anticoagulation.
cont. reading
